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tGenome-Wide Analysis Shows Increased Frequency of
Copy Number Variation Deletions in Dutch
Schizophrenia Patients
Jacobine E. Buizer-Voskamp, Jan-WillemMuntjewerff, Genetic Risk and Outcome in Psychosis (GROUP)
Consortium, Eric Strengman, Chiara Sabatti, Hreinn Stefansson, Jacob A.S. Vorstman, and
Roel A. Ophoff
Background: Since 2008, multiple studies have reported on copy number variations (CNVs) in schizophrenia. However, many regions are
unique events with minimal overlap between studies. This makes it difficult to gain a comprehensive overview of all CNVs involved in the
etiology of schizophrenia. We performed a systematic CNV study on the basis of a homogeneous genome-wide dataset aiming at all CNVs
50 kilobase pair.We complemented this analysiswith a reviewof cytogenetic and chromosomal abnormalities for schizophrenia reported
in the literature with the purpose of combining classical genetic findings and our current understanding of genomic variation.
Methods: We investigated834Dutch schizophreniapatients and672Dutchcontrol subjects. TheCNVswere included if theyweredetected
by QuantiSNP (http://www.well.ox.ac.uk/QuantiSNP/) as well as PennCNV (http://www.neurogenome.org/cnv/penncnv/) and contain
known protein coding genes. The integrated identification of CNV regions and cytogenetic loci indicates regions of interest (cytogenetic
regions of interest [CROIs]).
Results: In total, 2437 CNVs were identified with an average number of 2.1 CNVs/subject for both cases and control subjects. We observed
significantly more deletions but not duplications in schizophrenia cases versus control subjects. The CNVs identified coincide with loci
previously reported in the literature, confirming well-established schizophrenia CROIs 1q42 and 22q11.2 as well as indicating a potentially
novel CROI on chromosome 5q35.1.
Conclusions: Chromosomal deletions are more prevalent in schizophrenia patients than in healthy subjects and therefore confer a risk
factor for pathogenicity. The combination of our CNVdatawith previously reported cytogenetic abnormalities in schizophrenia provides an
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S chizophrenia is a debilitating psychiatric disease showing aheterogeneous clinical phenotype and a lifetime risk of.46%–1% (1,2). It is characterized by psychotic symptoms,
ncluding delusions and hallucinations, reduced interest and drive,
ltered emotional reactivity, and disorganized behavior (3). Its pre-
isposition is influenced by a complex interaction of genetic and
nvironmental factors (4,5). Family, twin, andadoption studieshave
rovided evidence for a substantial genetic contribution to the
henotypic varianceof schizophrenia (6). It hasbeenestimated that
heheritability of developing schizophrenia is up to 80% (7), but the
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lusive.
Early genetic studies in schizophrenia were based on linkage
tudies in pedigrees and association testing of candidate genes (8).
inkage and association studies havebeen complementedby iden-
ification of chromosomal abnormalities in patients as well as the
ore recentlygenome-wideassociation studies (GWAS)with single
ucleotide polymorphisms (SNPs). These genomicmicroarrays also
llowed for the systematic genome-wide analysis of submicrosco-
ic cytogenetic variation (i.e., genomic copy number variation
CNV]), which includes genomic deletions and duplications ofmore
han 1 kilobase pair (kb) in size. Many recent studies support a
olygenic basis of schizophrenia. Important in the understanding
f the genetic architecture of schizophrenia is the “common dis-
ase—common variant” versus the “common disease—rare vari-
nt” hypothesis. The first refers to the possibility that common
lleles with small-to-moderate disease risksmight have an additive
r multiplicative effect on schizophrenia. Recent large-scale associ-
tion studies have supported this hypothesis for schizophrenia (9).
owever, common variants are unlikely to explain the total herita-
ility of schizophrenia. The latter hypothesis suggests thatmultiple
are variants with relatively large effect play a role in the etiology of
chizophrenia. It is likely that both common and rare alleles lead to
he genetic heterogeneity of schizophrenia. Current CNV studies
avemainly focused on extremely rare and de novo variants. How-
ver, advances in CNV discovery techniques as well as the increas-
ng number of data releases from SNP association studies might
llow for the detection of smaller, more frequent variants (8).
Since 2008, several large-scalewhole-genome schizophrenia as-ociation studies have reported on the detection of CNVs (10–15).
BIOL PSYCHIATRY 2011;70:655–662































































































656 BIOL PSYCHIATRY 2011;70:655–662 J.E. Buizer-Voskamp et al.Over 41% of all CNVs identified overlap with known genes. This
suggests that CNVs might play a substantial role in modulating
geneexpression (16). Two large-scale studies identified three recur-
rent but rare schizophrenia-associated microdeletions at chromo-
some1q211, 15q13.3, and 15q11.2, each containingmultiple genes
(11,12). Many recurrent CNV loci are flanked by segmental duplica-
tions or low copy repeats (LCRs), which suggests that these dele-
tions andduplications couldbe the result of nonallelic homologous
recombination mediated by these LCRs. Large-scale CNV studies
suggest that rare variants disrupting genes in neurodevelopmental
pathways might significantly contribute to the risk for developing
schizophrenia (odds ratios ranging from 2.7 to 14.8) (8,12,14). How-
ever, many regions reported in those studies are unique events,
with minimal overlap between studies, with the exception of a few
recurrent loci (8). Both phenotypic diversity associated with CNVs
and heterogeneity in diagnoses and ethnicities could explain the
difficulties in replicating disease variants (17).
Few studies provided genome-wide evaluation of CNVs
11,12,18). However, most CNV studies thus far present a targeted
nd limited number of strong CNV candidates involved in disease.
elatively few investigators have yet reported their complete CNV
atasets or released raw data to the scientific community, minimiz-
ng the opportunity for comparing data or for meta-analyses (19).
owever, an overview of large-scale genomic variation will be a
rucial resource in correlating genomic variations with experimen-
al findings and clinical outcomes. A good example of a genome-
ide overview of all CNVs found in schizophrenia is the ISC (Inter-
ational Schizophrenia Consortium) study (12) that reports all CNVs
assing QC as an online datafile (http://pngu.mgh.harvard.edu/
sc/). A systematic review of cytogenetic and CNV findings would
rovide researchers in the field of schizophrenia with an overview
f potentially interesting regions for positional candidate genes.
ood examples from other research fields are, for example, the
atabase of Genomic Variants (http://projects.tcag.ca/variation/)
nd systematic information on chromosome rearrangements for
utism spectrum disorders (20,21).
We performed a two-step study. First, we carried out a system-
tic genome-wide CNV analysis in a homogeneous group of Dutch
chizophrenia cases versus unaffected control subjects andprovide
ata of all copy number variants of50 kb, including common and
are variants. We further performed a systematic review of all cyto-
enetic and chromosomal abnormalities reported in the literature
or schizophrenia, with the purpose of presenting a comprehensive
verview and combining classical cytogenetic findings and our
urrent understanding of genomic variation (22,23). We hypothe-
ize that (new) risk loci for schizophreniamightbe revealed through
verlap between genomic regions affected by previously reported
ytogenetic abnormalities and those affected by CNVs. In addition,
e also investigated CNVs in known candidate gene loci from liter-
ture. We hypothesize that those candidate gene loci will be af-
ectedbyCNVsmoreoften in cases comparedwith control subjects.
oth steps are a first effort to understand the role of genomic
hromosomal variation and schizophrenia susceptibility. We be-
ieve that these data, which we have made publicly available, are a
ecessary step toward that goal.
Methods andMaterials
Systematic Genome-Wide CNV Analysis
We studied CNVs within a cohort of 834 patients with schizo-
phrenia and 672 unaffected control individuals. Inpatients and out-
patients were recruited from a variety of psychiatric hospitals and
institutions in the Netherlands, partly coordinated via academic m
www.sobp.org/journalospitals in Amsterdam, Groningen, Maastricht, and Utrecht (The
enetic Risk and Outcome of Psychosis [GROUP] project). All pa-
ients hadbeendiagnosed for subtypes of schizophrenia according
o the DSM-IV-TR. Detailed medical and psychiatric histories were
ollected, including the Comprehensive Assessment of Symptoms
nd History, an instrument for assessing diagnosis and psychopa-
hology. The control subjects were volunteers and were all
creened for any psychiatric history, the majority via the Compre-
ensive Assessment of Symptoms and History. Both cases and con-
rol subjects were of Dutch descent (with at least three of four
randparents of Dutch ancestry), and they all gave informed con-
ent. The study was approved by the Ethics Committee of the Uni-
ersity Medical Center Utrecht and by the appropriate local institu-
ional review boards at all other participating hospitals.
GenomicDNAofallpatientsandcontrol subjectswashybridizedto
umanHap550v3 BeadArray (Illumina, San Diego, California) accord-
ng to standard protocols. QuantiSNP (http://www.well.ox.ac.uk/
uantiSNP/) (24) and PennCNV (http://www.neurogenome.org/cnv/
enncnv/) (25) were used to identify copy number deletions and
uplications. Both QuantiSNP and PennCNV are based on a Hidden
arkovModel for kilobase-resolutiondetectionof CNVs from Illumina
igh-densitySNPgenotypingdata. ThePennCNVprogramisprobably
he most frequently used program for CNV studies in recent publica-
ions. This might in part be due to the user-friendly design of the
rogramand free access to users. Its low false positive rate is a promis-
ngaspect. By contrast,QuantiSNPoutperformedsixothermethods in
recent evaluation study of CNV calling algorithms (26).
For QuantiSNP, a quality control step for GC-content was per-
ormed. For PennCNV, a gc-model for GC-correction was used, and
he following quality control steps were performed: 1) CNVs con-
aining10 consecutive SNPmarkers were excluded, 2) CNVs with
value below .5 for the confidence score (value for quality of the
NVcall) dividedby thenumberof SNPmarkerswereexcluded, and
) CNVs with an SNP density below 10 kb were excluded.
The CNVs were included only if they were detected by both
ennCNV and QuantiSNP andmeeting the aforementioned quality
ontrol criteria. Several CNV detection methods are available, but
ifferences in characteristics exist, and every method has its own
eaknesses (26). By including only overlapping CNVs, we made an
ffort to limit the false positive rate of CNV detection, as suggested
y Winchester et al. (27). The CNVs detected by both algorithms
ere defined by overlapping start and stop positions with at least
ne position (start or stop SNP marker) similar or when a smaller
NV completely overlapped a larger CNV. Moreover, we only in-
luded CNVs containing known protein coding genes, with fuzzy
order criteria of up to 50 kb surrounding the CNV boundaries.
ompared with CNV size, gene content might be a more reliable
ndicator for clinical significance, such that small gene-rich CNVs are
ore likely to be pathogenic than larger gene-poor CNVs (28). The
ene content of each CNV was defined with the UCSC genome
rowser (http://genome.ucsc.edu/). We investigated the reliability
f our CNVdataset by: 1) calculating the concordance rate between
alls from PennCNV and QuantiSNP, 2) calculating the percentage
f overlap between calls from the two datasets when increasing
ltering stringency, and 3) validating individual CNVs by multiplex
igation-dependent probe amplification and quantitative polymer-
se chain reaction (qPCR). Taken together, by focusing our analysis
n those CNVs that were consistently called by the two algorithms
nd contain known protein coding (RefSeq) genes, we generated a
eliable dataset for further testing.
We provide all data of CNVs 50 kb found in both cases and
ontrol subjects. Raw data are available for future research and















































































J.E. Buizer-Voskamp et al. BIOL PSYCHIATRY 2011;70:655–662 657pared the number of deletions and duplications for different size
categories in cases and control subjects.
Reviewing Literature
Studies were identified by searching the electronic National
Library ofMedicineMEDLINE and PubMeddatabaseswith different
combinations of the search terms “schizophren*,” “genetic*,” “cyto-
genetic*,” “copy number,” “CNV,” and “chromosom*” for reports
published until January 2010. All studies were examined with a
special emphasis on the quality of the schizophrenia diagnosis and
the definition of the chromosomal aberration. The quality of the
phenotype was rated for each case by two investigators (JWM and
JEB) (Cohen’s  .68; p  .001). Ratings were based on the clinical
escription, the presence of a psychiatric diagnosis, or a classifica-
ion system (Table S4 in Supplement 1). This permitted a ranking of
egions on the basis of the most valid clinical diagnosis of schizo-
hrenia.
Becausewe focusedongene-containingCNVsmost probable to
ave pathogenic effects in our CNV analysis, we compared the
hole-genome CNV data with cytogenetic abnormalities found in
ase reports. Cytogenetic visible deletions and duplications might
onstitute a less common but potentially stronger influence on risk
or schizophrenia, and these are likely to havedirect effects ongene
xpression. Because of their relatively large size, these chromo-
omal aberrations might encompass multiple genes, which sug-
ests a role in modulating gene expression (29). For example, it is
uggested that the combined haploinsufficient expression of mul-
iple genes in the 22q11 microdeletion causes the high rates of
chizophrenia observed in patients with this 3-Mb deletion syn-
rome (encompassing 30 genes) (22). We were able to select, from
oth the CNV and cytogenetic abnormality loci, cytogenetic re-
ions of interest (CROIs): loci where at least one case report and
woDutch schizophrenia CNV cases overlapped. Together with a
ystematic review of CNV findings from the literature, we high-
ight (new) chromosomal variation loci for schizophrenia suscep-
ibility.
We were interested, in addition to selecting CROIs, to see
hether we were able to combine our CNV findings and literature
oci in a different way. For this sub-analysis we included all articles
escribing CNVs in schizophrenia patients (Table S3 in Supplement
) with special emphasis on the description of candidate genes
esiding in these loci. We counted all deletions and duplications
rom our CNV analysis showing overlap with the candidate gene
oci from the literature. Cases and control subjects were compared
n the number of deletions and duplications within these regions.
See Tables S2, S3, and S4 in Supplement 1 for further details on
he methods.
Results
Systematic Genome-Wide CNV Analysis
In total, 7211 CNVs passed the quality control for QuantiSNP,
and 21,182 CNVs passed for PennCNV. More than 50% of all CNVs




All 470 326 796
50 kb 375 226 601
500 kb 18 4 22
1 Mb 11 2 13CNV, copy number variation.ere gene-containing: 3767 for QuantiSNP, and 13,849 for
ennCNV. In total, 2437 gene-containing CNVs were called by both
lgorithms andwere included in the study. These CNVswere found
n 659 unique cases and 508 unique control subjects.
The poor overlap between QuantiSNP and PennCNV is striking,
lthough not unusual (26,27,30). A recent study by Dellinger et al.
26) compared, among others, the PennCNV and QuantiSNP algo-
ithms and found that the average number of detected CNVs
iffered, depending on the algorithm. The call numbers were
orrelated to sensitivity, specificity, and . Tsuang et al. (31) also
emonstrated that the number of CNVs identified depends on
he algorithm(s) used. They showed, in accordance with our own
ndings, that PennCNV called far more CNVs compared with
uantiSNP.
It is known that modifying parameters affects CNV detection.
he number of calls as well as the size of predicted CNVs are af-
ected (26,27). When relaxing some of the parameter settings, we
aw differences in the number of CNV calls also influencing the
umber of overlapping CNVs of both algorithms (data not shown).
hen increasing the filtering stringency from 10 to 30 consecutive
NP markers, we observed more overlapping CNVs between
ennCNV and QuantiSNP, which affect especially CNVs of larger
ize. The total overlap percentage between the two datasets in-
reased from 27.4% to 46.8%. The use of overlapping calls from
oth algorithms should increase the confidence of our dataset and
ives clearer indications of the CNV boundaries (27,31).
To investigate the reliability of our CNV dataset, we visually
nspecteda set of commonand rareCNVs. RareCNVsweredetected
n one patient only. Inspection of their intensity plots revealed that
hey were likely to be true CNV loci. We selected and validated, on
he basis of their gene content, four CNVs by either multiplex liga-
ion-dependent probe amplification (duplication 2p25.3, deletion
p16.3, anddeletion9q33.1) or genomicqPCR (duplication5p15.2),
s described previously (13). All four CNVs were confirmed as true
ositive finding. We also investigated nine duplicate samples to
alculate a concordance rate between calls from PennCNV and
uantiSNP. The calls were highly correlatedwith a correlation coef-
cient of .81.
The average number of gene containing CNVs/subject was 2.1
or both cases and control subjects. One subject can have multiple
eletions or duplications of different lengths. Therefore, groups of
eletions or duplications categorizedby size across subjects arenot
utually exclusive. When we limited our analysis to a subject hav-
ng just one or more CNV/type and size, we indicated a total of 796
eletions (Table 1) and 827 duplications (Table 2). Cases seemed to
ave significantly more deletions compared with control subjects
or all different size categories (Table1).However,wedidnotfindany
ignificant difference between cases and control subjects for duplica-
ions (Table 2). This is in accordance with the literature, stating that
eletionsmight bemore pathogenic than duplications (28).
We identified a total of 1896 CNVs of 50 kb observed in 433



























658 BIOL PSYCHIATRY 2011;70:655–662 J.E. Buizer-Voskamp et al.only included overlapping results of the two CNV detection meth-
ods with the purpose of increasing our confidence of the CNV calls.
QuantiSNP yielded 3195 CNVs, whereas PennCNV analysis resulted
indetectionof 10,641CNVs; overlapbetween the twomethodswas
27.4%. These findings (including exact base pair [bp] boundaries)
are presented in Tables S1 and S2 in Supplement 1. Some of our
CNVs overlap regions of LCRs. Previous analyses showed significant
associations between LCRs and CNV regions (32–34). However, the
HumanHap550v3 BeadArraywe used for SNP genotyping primarily
targets SNP loci at nonrepetitive genomic regions. Furthermore,
the rate of LCR-flanking CNVs is not different between cases and
control subjects (data not shown). The LCR-mediated CNVs should
therefore have limited effect in our analyses.We foundno evidence
for increased double hit rate (i.e., multiple CNVs/subject) in schizo-
phrenia patients compared with control subjects. In Figure 1, all
CNVs500 kb (n 60) are represented to scale on each chromo-
some. Genes reported to be associated with schizophrenia are also
indicated.




All 455 372 827
50 kb 417 344 761
500 kb 39 27 66
1 Mb 14 9 23
CNV, copy number variation.
Figure 1. CNVs in 834 Dutch schizophrenia patients and 672 Dutch control
variations (CNVs) in 834 Dutch schizophrenia cases and 672 Dutch contro
indicated. On the right side of each chromosome, CNVs of schizophrenia cases ar
In green, schizophrenia-associated genes from CNV literature are indicated.
www.sobp.org/journalThe graphical overview of this systematic genome-wide CNV
nalysis shows sites of increased deletions in cases versus control
ubjects for: 4q35.2, 15q13.2-q13.3, and 22q11.21. Interesting sites
f increased duplications in cases versus control subjects are
q42.3-43, 2p25.3, and 17q25.1. When examining loci of candidate
enes for schizophrenia indicated by previous CNV studies, we
bserve significantly more CNV deletions of 50 kb within these
ene regions for cases compared with control subjects (p value
0004). However, there is no significant difference for CNV duplica-
ions of50 kb within these candidate gene regions (p value 1)
Table 3). The regions on chromosome 1q, 2p, 15q, and 22q have
reviously been highlighted in cytogenetic and CNV studies (10–
5,18,35–38). The 4q35.2 region (188,329,837–191,164,126 bp) is a
ossible novel CNV region-of-interest, indicated by three schizo-
hrenia caseswith thedeletion versus only one control subject. Our
uplications at chromosome 17q (69,345,596–71,746,800 bp) in
our cases and no control subjects were also not previously de-









cts. Representation of a systematic genome-wide survey for copy number
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An overview of all cytogenetic abnormalities described in litera-
ture can be found in Figure S2 and Table S4 in Supplement 1. It
seems that schizophrenia susceptibility loci are not equally distrib-
uted across the human genome but rather cluster together in spe-
cificCROIs.Whenwecompare cytogenetic abnormalitieswithCNVs
found in Dutch schizophrenia cases and control subjects, we ob-
serve the followingCROIs: 1q42, 5q35.1, 7q21.12-q21.13, and22q11
(Figure 2). These regions are reported by at least one cytogenetic
study and have CNVs in at least two cases. The regions on chromo-
some 1q and 22q have been described before (10–12,14,15,18,35–
38) and also appeared as interesting sites in our CNV analysis. Our
CNV on 1q42, although overlapping the large region from the 1;11
translocation, is not overlapping the exact boundaries of the DISC1
gene (approximately 3 Mb between CNV and gene region). For the
22q11.2 region we find both deletions and duplications (Figure S3
in Supplement 1). This region is known from the 22q11.2 Deletion
Syndrome (MIM ID #188400). Most patients with this syndrome





A2BP1 (15) 16p13.2 4
ADAMTSL3 (18) 15q25.2 0
ADORA2A (47) 22q11.23 0
APBA2 (18,48,49) 15q13.1 0
ASTN2 (13) 9q33.1 0
CABIN1 (47) 22q11.23 0
CHRNA7 (11,12) 15q13.3 3
CIT (15) 12q24.23 0
CNTNAP2 (50) 7q35–q36.1 3
COMT (37,38) 22q11.21 1
CTNND2 (13) 5p15.2 0
CYFIP1 (11) 15q11.2 7
DISC1 (51) 1q42.2 0
DLGAP2 (48) 8p23.3 0
DOC2A (48) 16p11.2 0
EFCAB2 (18) 1q44 0
ERBB4 (14) 2q34 1
GJA8 (11) 1q21.1 0
GSTM1 (47) 1p13.3 0
GSTT2 (47) 22q11.23 0
KIF26B (18) 1q44 1
MAPT (48) 17q21.31 0
MYT1L (13) 2p25.3 0
NDE1 (52) 16p13.1 0
NDNL2 (48) 15q13.1 0
NOTCH4 (41,53) 6p21.32 0
NRGN (41) 11q24.2 0
NRXN1 (13,14,18,48,49) 2p16.3 3
NTAN1 (52) 16p13.1 0
PGBD1 (41) 6p22.1 0
PI4KCA (47) 22q11.21 2
PRODH (37,38) 22q11.21 11
RAPGEF6 (15) 5q31.1 0
SLC1A3 (14) 5p13.2 0
SSTR5 (47) 16p13.3 0
TJP1 (48) 15q13.1 0
Total 36
Deletions (Del) p .0004. Duplications (Dup) p 1.
CNV, copy number variation.share a 3-Mb loss, although a nested 1.5-Mb deletion is also ob- perved alongwith infrequent atypical deletions. The LCRs are flank-
ng andmediating the deletion regions (39). We identified 12 dele-
ions within the 22q11.2 interval. Of these, 1 (case) was consistent
ith the largerdeletion, 0were consistentwith the shorterdeletion,
nd 11 (9 cases and 2 control subjects; 729 kb: 19,063–19,792 kb;
56 kb: 17,258 kb –17,434 kb) were atypical. For chromosome 7,
lthough found in two cases and one cytogenetic study, also two
ontrol subjects are identified to have a duplication at this site.
hromosome 5q (168,385,055–169,072,475 bp) is a possible novel
egion, indicated by clustering of cytogenetic abnormalities and
NV findings. However, the only investigated candidate genes re-
iding in this locus are SLIT3, GABRP, and FGF18, with inconsistent
esults (http://www.schizophreniaforum.org/res/sczgene).
An overview of all CNV studies from literature can be found in
able S3 in Supplement 1. Lack of information about the real num-
er of CNVs occurring in cases and control subjects and unclear
iagnostic criteria limited our ability to give a complete and correct





Del Dup Del Dup
3 (.69) — 1 (.28) 3 (.85)
— — — —
— — — —
— — — —
— 1 (.23) — —
— — — —
3 (.69) — — 2 (.56)
— — — —
3 (.69) — — —
1 (.23) — — —
— 1 (.23) — —
4 (.92) 6 (1.39) 3 (.85) 4 (1.13)
— 3 (.69) — 2 (.56)
— — — —
— — — —
— 1 (.23) — —
1 (.23) — — —
— — — —
— — — —
— — — 1 (.28)
1 (.23) 1 (.23) — —
— — — —
— 2 (.46) — —
— 3 (.69) — 3 (.85)
— — — —
— — — —
— — — —
3 (.69) 1 (.23) — 1 (.28)
— 3 (.69) — 1 (.28)
— — — —
2 (.46) — — 1 (.28)
9 (2.08) 13 (3.0) 2 (.56) 10 (2.82)
— — — —
— — — —
— — — —
— — — —






































































660 BIOL PSYCHIATRY 2011;70:655–662 J.E. Buizer-Voskamp et al.tered regions of interest (e.g., on chromosome 1q, 15q, and 22q11)
(Figure S1 and Table S3 in Supplement 1).
Discussion
We performed a genome-wide analysis of CNVs in 834 schizo-
phrenia cases and 672 unaffected control subjects from the Neth-
erlands. The most apparent observation is that cases showed sig-
nificantly more deletions for all size categories, an effect not seen
for duplications.When focusingonpreviously reported schizophre-
nia-candidate CNV loci, a similar effect was observed, with cases
showing significantly more deletions compared with control sub-
jects. These findings suggest that deletion CNVs might be more
prevalent in individuals with schizophrenia and therefore confer a
higher risk factor for pathogenicity. This is in linewith previous CNV
studies that also suggested thatduplications aregenetic alterations
that are better tolerated in the genome and that deletions have a
higher likelihood of being pathogenic (19,28).
Additionally, we reviewed all cytogenetic and chromosomal ab-
normalities described for schizophrenia patients (Table S4 in Sup-
plement 1). The integrated identification of CNV regions and cyto-
genetic and chromosomal loci highlight the following regions of
interest (CROIs): 1q42, 2p25, 15q13, and 22q11 as loci previously
described. Secondly, we identified 4q35 (increased number of de-
letions in cases compared with control subjects) and 17q25 (in-
Figure 2. Copy number variations (CNVs) in 834 Dutch schizophrenia cases
hromosome, chromosomal aberrations from literature are indicated. On the
ia cases are indicated. Blue bars represent duplications or gains, red bars r
nversions. Blue boxes indicate regions where at least one chromosomal ab
2q11.2 were previously indicated by linkage (54,55) or association studie
hromosome 5q35 and on chromosome 7q21.12-q21.13 are potentially nov
ase pair boundaries of overlap regions we refer to Tables S1 and S4 in Supcreased number of duplications in cases compared with control G
www.sobp.org/journalubjects) as CROIs from our CNV analysis. An interesting region
rom the integration of CNVs and cytogenetic abnormality re-
orts is 5q35. Furthermore, we see regions of genomic variation
xisting both in cases and in control subjects. These CNVs are
ery difficult to interpret in the absence of further correlative
ata.
It is probable that a combination of both common and rare risk
ariants is involved in schizophrenia etiology. CommonCNVs (allele
requency 5%) are almost always inherited and comprise most
NVdifferencesbetween individuals (19). In two recent largeGWAS
tudies for schizophrenia, TCF4 and ZNF804A have been found as
est hits (40,41). These are transcription factors thatmight regulate
xpression of many genes. This raises the possibility that common
ariation might confer susceptibility to schizophrenia. However,
ntil now, mostly rare (.5%–1%) and large (100 kb) CNVs have
een implicated in schizophrenia (42). This study both confirms the
nvolvement of the recurrent variants (e.g., for 1q42) and adds to the
mplication of rare CNVswith an elevated risk for schizophrenia (43).
Improvement of genomic array and sequencing technologies
ill providehigher-resolution andmore accuratedetectionofCNVs
44). These new technologies will aid the discovery of new schizo-
hrenia risk regions and candidate genes. In addition to technolog-
cal advances, there is need for development of improved algo-
ithms and statistical methods for reliable CNV calling in existing
ared with cytogenetic aberrations from literature. On the left side of each
t side of each chromosome, copy number variants in 834Dutch schizophre-
ent deletions or losses, and green bars represent balanced translocations/
ion and two copy number cases overlapped. The regions 1q42.3-q43 and
,57) and often supported by CNV findings from literature. The regions on




























J.E. Buizer-Voskamp et al. BIOL PSYCHIATRY 2011;70:655–662 661algorithms, so the use of multiple algorithms specific to the array
platform used seems recommended (31). Moreover, it is important
that studies with large sample sizes will make their CNV calls pub-
licly available for further study and systematic meta-analyses (e.g.,
via theDatabaseofGenomicVariants). Newbioinformatic tools that
combine different genomic data sources are necessary to gain bet-
ter insight into this complex psychiatric disorder.
It is possible that our study is subject to various kinds of biases.
First, overrepresentation of some regions in our literature study
might represent availability of probes rather than significant asso-
ciation with schizophrenia. This is clearly the case for the 22q11
deletion, which results in reporter bias. When a specific region has
been linked to schizophrenia, the locus becomes more interesting
for research, resulting in more tested cases. In our effort to include
previously reported cytogenetic abnormalities in schizophrenia,
we noticed that approximately one-third of the cases showed ei-
ther mental retardation or physical anomalies. For CNV studies in
literature, by contrast, this type of clinical data was not always
mentioned. However, both features are associatedwith a high inci-
dence of cytogenetic abnormalities (45). Therefore, the loci indi-
cated in this study might be linked to mental retardation and dys-
morphic features rather than to the schizophrenia phenotype
alone.
For complex traits like schizophrenia, it is important to consider
all classes of variation: cytogenetic abnormalities as well as SNPs
and CNVs (46). This study provides a comprehensive overview of all
CNVs 50 kb found in a homogeneous Dutch sample of schizo-
phrenia cases and unaffected control subjects. Deletions are more
prevalent in schizophrenia patients and might confer a higher risk
factor thanduplications.Wecombined thesedatawith a systematic
overview of cytogenetic and CNV findings from the literature. Our
results confirm the already-known results for, for example, the
15q13 and 22q11.2 deletions and highlight novel candidate re-
gions. These regions indicate how classical cytogenetic findings
and our current understanding of genomic variation can be com-
bined and might contain loci with rare variants contributing to
disease susceptibility. By reporting our complete CNV dataset and
systematically reviewing the literature, we hope this study is a step
toward understanding the role of genomic chromosomal variation
in schizophrenia etiology. Future studies will include genome-
wide sequencing, so the whole spectrum of genomic and ge-
netic variation can be examined for involvement in schizophre-
nia susceptibility.
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